Latest Breaking News On - உதவி பப்ளிக் - Page 1 : comparemela.com
Specific Diagnostics Announces Results of Two Studies at Hospitals Within AP-HP (Assistance Publique-Hôpitaux de Paris) Evaluating Performance of Reveal Rapid AST System
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Scientists are honing their weapons to fight Covid-19
scienceblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblog.com Daily Mail and Mail on Sunday newspapers.
the global fight against this disease.”
Investigators and the Independent Data Monitoring Committee observed slightly higher deaths in the treatment arm compared to placebo without causality being established. Results from this trial, including translational data, are planned to be submitted for publication.
Based on these results, the Company will stop exploring avdoralimab in COVID-19. Today’s results do not impact the investigator-sponsored, Phase 2 trial of avdoralimab in bullous pemphigoid, an inflammatory disease, which is currently enrolling patients. More than 100 patients have been treated with avdoralimab in inflammation and oncology clinical trials with no new or unexpected safety signals observed.
About the FORCE clinical trial:
Company will stop exploring avdoralimab in COVID-19
Investigator-sponsored avdoralimab clinical trial in inflammation will continue
MARSEILLE, France, July 06, 2021 (GLOBE NEWSWIRE) Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“
Innate” or the “
FOR COVID-19
Elimination), the investigator-sponsored, Phase 2 clinical trial evaluating the safety and efficacy of its anti-C5aR1 antibody, avdoralimab, in COVID-19 patients with severe pneumonia, did not meet its primary endpoints in all three cohorts of the trial.
The FORCE trial was initiated based on pre-clinical data showing that patients who progress towards severe COVID-19 disease exhibit an activation of the C5a/C5aR1 pathway. These translational data were observed in the trial; however, they did not translate into clinical benefit over best supportive care.
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis | Critical Care Medicine | JAMA
jamanetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jamanetwork.com Daily Mail and Mail on Sunday newspapers.